8 results on '"Gabazza, E. C."'
Search Results
2. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
- Author
-
Watanabe R, Wada H, Miura Y, Murata Y, Watanabe Y, Sakakura M, Okugawa Y, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Shiku H, and Nobori T
- Subjects
- Antifibrinolytic Agents analysis, Antithrombin III analysis, Biomarkers, Disseminated Intravascular Coagulation complications, Disseminated Intravascular Coagulation diagnosis, Endothelium, Vascular pathology, Fibrin Fibrinogen Degradation Products analysis, Fibrinolysin analysis, Fibrinolysis, Hematologic Neoplasms blood, Hematologic Neoplasms complications, Humans, Macromolecular Substances, Multiple Organ Failure blood, Multiple Organ Failure etiology, Neoplasms blood, Neoplasms complications, Peptide Hydrolases analysis, Plasminogen Activator Inhibitor 1 metabolism, Protein Binding, Purpura, Thrombotic Thrombocytopenic complications, Sepsis blood, Sepsis complications, Thrombomodulin blood, Tissue Plasminogen Activator metabolism, alpha-2-Antiplasmin analysis, Disseminated Intravascular Coagulation blood, Plasminogen Activator Inhibitor 1 analysis, Purpura, Thrombotic Thrombocytopenic blood, Tissue Plasminogen Activator analysis
- Abstract
In this study, we examined changes in the plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tissue-type plasminogen activator (tPA)/PAI-I complex in patients with disseminated intravascular coagulation (DIC) and in those with thrombotic thrombocytopenic purpura (TTP) to investigate the fibrinolytic function and its relation to organ failure. The plasma levels of total PAI-1 and tPA/PAI-I complex were significantly higher in patients with DIC, pre-DIC, and TTP than in those with non-DIC. The plasma levels of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer, thrombomodulin (TM), total PAI-I, and tPA/PAI-I complex were significantly higher in patients with organ failure than in those without organ failure. The plasma levels of total PAI-I and tPA/PAI-I complex were markedly increased in patients with acute leukemia. The plasma levels of total PAI-I, but not those of tPA/PAI-I complex, were significantly increased in patients with sepsis or with solid cancer. In all cases, total PAI-I or tPA/PAI-I complex was not significantly correlated with any hemostatic marker. Measurement of total PAI-I and tPA/PAI-I complex may be useful in the diagnosis of DIC.
- Published
- 2001
- Full Text
- View/download PDF
3. Increased plasma thrombomodulin as a vascular endothelial cell marker in patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
- Author
-
Mori Y, Wada H, Okugawa Y, Tamaki S, Nakasaki T, Watanabe R, Gabazza EC, Nishikawa M, Minami N, and Shiku H
- Subjects
- Adolescent, Adult, Aged, Biomarkers blood, Child, Child, Preschool, Endothelium, Vascular injuries, Hemolytic-Uremic Syndrome etiology, Hemolytic-Uremic Syndrome mortality, Hemostatics blood, Humans, Infant, Infant, Newborn, Middle Aged, Purpura, Thrombotic Thrombocytopenic mortality, Survival Rate, Treatment Outcome, Endothelium, Vascular pathology, Hemolytic-Uremic Syndrome blood, Purpura, Thrombotic Thrombocytopenic blood, Thrombomodulin blood
- Abstract
Several hemostatic and vascular endothelial cell markers were measured in 39 patients with thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) and in 20 healthy volunteers to examine the relationship between the occurrence of hemostatic abnormality or vascular endothelial cell injury and patient outcome. The plasma levels of von Willebrand factor, tissue plasminogen activator (TPA), plasminogen activator inhibitor (PAI-1), and the TPA-PAI-1 complex were significantly increased in TTP/HUS patients; however, the levels of these markers were not significantly different between TTP/HUS patients who survived and those who died, suggesting that these markers might not be directly related to outcome. The plasma levels of soluble granule membrane protein (GMP)-140 were significantly higher in TTP/HUS patients than in healthy volunteers, suggesting that platelets and vascular endothelial cells are activated or injured in TTP/HUS. There was no significant difference in GMP-140 levels between TTP/HUS patients with good and poor prognoses; this may be owing to the release of GMP-140 from platelets. The plasma thrombomodulin (TM) levels in TTP/HUS patients were significantly higher than in healthy volunteers; the plasma TM levels were significantly higher in patients who died than in patients who survived. These findings showed that TM levels reflect the outcome and that the outcome of TTP/HUS depends on the presence vascular endothelial cell injury. The plasma protein C and antithrombin levels were markedly reduced in TTP/HUS patients who died compared with those who survived. These findings suggest that reduced plasma antithrombin and protein C may be useful markers of systemic vascular endothelial injury. In conclusion, the results of this study showed that the outcome of TTP/HUS is related to vascular endothelial cell injury and that plasma TM, antithrombin, and protein C levels may be useful markers of systemic vascular endothelial cell injury.
- Published
- 2001
- Full Text
- View/download PDF
4. Changes of hemostatic molecular markers after gynecological surgery.
- Author
-
Noda K, Wada H, Yamada N, Noda N, Gabazza EC, Kumeda K, Okugawa T, Yanoh K, Ito M, Nakano T, Shiku H, Nobori T, Kato H, and Toyoda N
- Subjects
- Adult, Aged, Antithrombins metabolism, Biomarkers blood, Endometrial Neoplasms complications, Endometrial Neoplasms surgery, Female, Genital Neoplasms, Female complications, Genital Neoplasms, Female surgery, Humans, Middle Aged, Neoplasms complications, Neoplasms surgery, Partial Thromboplastin Time, Platelet Count, Postoperative Complications, Protein C metabolism, Pulmonary Embolism blood, Pulmonary Embolism etiology, Risk Factors, Thrombosis blood, Thrombosis etiology, Time Factors, Gynecologic Surgical Procedures adverse effects, Hemostatics blood
- Abstract
The authors evaluated the hemostatic abnormalities occurring in the postoperative period of eight patients with malignant tumors and compared them with those occurring in the postoperative period of eight patients with benign tumors. Two of the patients with malignant tumor presented pulmonary embolism after operation. Plasma fibrinogen and fibrin degradation product levels in patients with malignant tumors were already high before operation and further increased significantly after operation. The plasma levels of D-dimer, thrombin-antithrombin complex, and free-tissue factor pathway inhibitor were increased in both groups after operation, but they were higher in patients with malignant tumors than in patients with benign tumors. The plasma levels of protein C and antithrombin were significantly decreased in both groups after operation. but they were significantly lower in patients with malignant tumors than in those with benign tumors. The decreased activity of protein C or antithrombin may be not only a risk factor of thrombotic disease, such as pulmonary embolism, but also the cause of thrombosis. In patients with malignant tumors, the operation time was significantly longer than that in patients with benign tumors. This long operative period might cause vascular endothelial cell injury which is reflected by the plasma levels of free-tissue factor pathway inhibitor, antithrombin, and protein C.
- Published
- 2000
- Full Text
- View/download PDF
5. Decreased protein C activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease.
- Author
-
Yasui H, Gabazza EC, Taguchi O, Risteli J, Risteli L, Wada H, Yuda H, Kobayashi T, Kobayashi H, Suzuki K, and Adachi Y
- Subjects
- Biomarkers, Blood Coagulation, Bronchoalveolar Lavage, Enzyme Activation, Female, Hemostatics, Humans, Lung Diseases, Interstitial metabolism, Male, Procollagen blood, Statistics, Nonparametric, Collagen metabolism, Lung Diseases, Interstitial etiology, Protein C metabolism, Pulmonary Alveoli metabolism
- Abstract
Activation of the coagulation system in the alveolar space plays an important role in the pathogenesis of interstitial lung disease (ILD) and pulmonary fibrosis. The protein C (PC) pathway is the main modulator of coagulation activation. This study evaluated whether dysfunction of the PC pathway is associated with increased collagen synthesis in the intraalveolar space of patients with ILD. This study comprised 22 patients with ILD; of these, five had idiopathic pulmonary fibrosis (IPF), nine had sarcoidosis-associated ILD, and eight had collagen vascular disease-associated ILD (CVD-ILD). Thrombin-antithrombin complex (TAT) was measured as a marker of coagulation activation. As markers of the PC pathway activity, the concentration of activated PC-PC inhibitor (APC-PCI) complex and the APC-PCI/PC ratio were measured and, as a marker of collagen synthesis, the concentration of aminoterminal propeptide of type III procollagen (PIIINP) was measured in bronchoalveolar lavage fluid (BALF) of ILD patients. TAT was significantly increased in BALF from ILD patients as compared to control subjects. The concentrations of PIIINP were significantly elevated in patients with ILD as compared to healthy subjects. In contrast, the concentration of APC-PCI and the values of APC-PCI/PC ratio were significantly decreased in BALF from patients with ILD. BALF concentration of PIIINP was significantly and inversely correlated with the concentration of APC-PCI and with the APC-PCI/PC ratio. These findings suggest that dysfunction of the protein C pathway may have important physiopathologic implications in the development of pulmonary fibrosis in ILD.
- Published
- 2000
- Full Text
- View/download PDF
6. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis.
- Author
-
Inoue A, Wada H, Takagi M, Yamamuro M, Mukai K, Nakasaki T, Shimura M, Hiyoyama K, Deguchi H, Gabazza EC, Mori Y, Nishikawa M, Deguchi K, and Shiku H
- Subjects
- Antithrombin III analysis, Biomarkers blood, Female, Fibrin Fibrinogen Degradation Products analysis, Hemostasis, Humans, Male, Middle Aged, Peptide Hydrolases analysis, Reference Values, Antifibrinolytic Agents blood, Antifibrinolytic Agents metabolism, Fibrinolysin metabolism, Lipoproteins blood, Renal Dialysis adverse effects, Thrombomodulin blood, Thromboplastin analysis, Thrombosis blood, Thrombosis etiology, alpha-2-Antiplasmin
- Abstract
Before hemodialysis (HD), plasma levels of tissue factor (TF), free-TF pathway inhibitor (TFPI) and thrombomodulin (TM) were significantly higher in patients with HD than in healthy volunteers. Plasma levels of (T-F) TFPI and plasmin plasmin inhibitor complex (PPIC) were significantly higher in patients with HD than in healthy volunteers. During HD, plasma levels of TF and (T-F) TFPI were not significantly increased, but plasma levels of total TFPI and free TFPI at 1 hour after and at the end of HD were significantly increased, compared with levels before start of HD. Plasma level of PPIC 1 hour after start of HD was significantly higher than before start of HD, and plasma levels of thrombin antithrombin complex (TAT), PPIC, D-dimer, TM, and protein C (PC) at the end of HD were significantly higher than before start of HD. In patients with thrombosis complications, plasma TF levels were significantly higher than in patients without thrombotic complications during HD. Plasma levels of PC were significantly lower in patients with thrombotic complications than in patients without thrombotic complications. There was no significant difference between both groups during HD in hemostatic parameters, with the exception of TF and PC. Hemostatic abnormalities existed in patients with HD; especially, increased TF and decreased PC might cause thrombotic complications.
- Published
- 2000
- Full Text
- View/download PDF
7. Elevated tissue factor levels in leukemic cell homogenate.
- Author
-
Nakasaki T, Wada H, Watanabe R, Mori Y, Gabazza EC, Kageyama S, Nishikawa M, and Shiku H
- Subjects
- Antigens, Neoplasm blood, Disseminated Intravascular Coagulation blood, Disseminated Intravascular Coagulation etiology, Humans, Leukemia complications, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Leukemia, Monocytic, Acute pathology, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Leukemia, Myelomonocytic, Acute pathology, Leukemia, Promyelocytic, Acute pathology, Leukemia, T-Cell pathology, Leukocytes, Mononuclear chemistry, Neoplasm Proteins blood, Neoplasm Proteins immunology, Neoplasm Proteins metabolism, Thromboplastin immunology, Leukemia pathology, Thromboplastin metabolism
- Abstract
Tissue factor (TF) antigen and activity were measured in leukemic cell homogenates. In leukemic cell homogenate, especially that of acute promyelocytic leukemia (APL), both TF antigen and activity were significantly higher than these levels in the mononuclear cells obtained from healthy volunteers. Both TF antigen and activity were significantly higher in myelocytic leukemia than in lymphocytic leukemia cells. In leukemic cell homogenates, there was a close correlation between TF antigen and TF activity. The TF activity/TF antigen ratio was significantly higher in myelocytic leukemia than in lymphocytic leukemia cells. As the TF activity was not increased in lymphocytic leukemia cell homogenates to which were added phospholipids, the decrease in TF activity in lymphocytic leukemia might not be due to phospholipid in the leukemic cell membrane. Values for TF activity, TF antigen, and the TF activity/TF antigen ratio in leukemic cell homogenate from patients with disseminated intravascular coagulation (DIC) were significantly higher than those in patients without DIC. Therefore, the measurement of TF antigen and activity in leukemic cells could be useful for the prediction of DIC.
- Published
- 2000
- Full Text
- View/download PDF
8. Aberrations of the tissue factor pathway in patients positive for lupus anticoagulant.
- Author
-
Wakita Y, Wada H, Nakase T, Nakasaki T, Shimura M, Hiyoyama K, Mori Y, Gabazza EC, Nishikawa M, Deguchi K, and Shiku H
- Subjects
- Adult, Anticoagulants blood, Anticoagulants immunology, Antifibrinolytic Agents metabolism, Antigens blood, Antithrombin III metabolism, Cell Culture Techniques, Cell Survival, Cohort Studies, Endothelium, Vascular metabolism, Endothelium, Vascular pathology, Factor Xa Inhibitors, Female, Fibrin Fibrinogen Degradation Products metabolism, Fibrinolysin metabolism, Fibrinolytic Agents blood, Fibrinolytic Agents immunology, Hemostatics, Humans, Lipoproteins blood, Lipoproteins immunology, Lupus Erythematosus, Systemic blood, Male, Middle Aged, Peptide Hydrolases metabolism, Serine Proteinase Inhibitors blood, Serine Proteinase Inhibitors immunology, Thromboplastin immunology, Thrombosis blood, Thrombosis metabolism, Umbilical Veins pathology, Lupus Coagulation Inhibitor blood, Thromboplastin biosynthesis, Thromboplastin metabolism, alpha-2-Antiplasmin
- Abstract
To evaluate the relationship between the tissue factor (TF) pathway and lupus anticoagulant (LA), in the present study, we measured the plasma levels of TF antigen and TF pathway inhibitor (TFPI) antigen in patients positive for LA. Plasma TF and TFPI levels in LA-positive patients were significantly higher than levels in healthy volunteers (p < 0.01). In LA-positive patients, there were no significant differences in plasma TF and TFPI levels between patients with and without thrombosis. In patients with thrombosis, there was no significant difference in the plasma TF level between LA-positive and LA-negative patients; however, the plasma TFPI level in LA-positive patients was significantly lower than that in LA-negative patients (p < 0.01). We also examined the TF pathway in human umbilical venous endothelial cells (HUVEC) incubated with plasma of LA-positive patients, LA-negative patients, and healthy volunteers. TF activity was significantly higher (p < .05) in HUVECs incubated with the plasma of LA-positive patients than in cells incubated with the plasma of the other two groups (p < .01). However, there was no significant difference in TFPI antigen levels among the media of HUVECs incubated with the plasma of all groups. The viability of HUVEC incubated with the plasma of LA-positive patients with thromboses, LA-positive patients without thromboses, and LA-negative patients with thromboses were significantly lower than that of HUVECs incubated with the plasma of healthy volunteers (p < .01). These findings suggest that abnormalities of the TF pathway plays an important role in the mechanism of hypercoagulability in LA-positive patients. LA may affect vascular endothelial cells causing thrombogenesis.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.